What Arcreal does
Arcreal builds arcscan, an intraoral scanner developed end-to-end in-house -- hardware, software, and AI models -- for dental clinics, and has received FDA clearance in the US and CE MDR approval in Europe. Founded in Seoul in May 2021, the company is completing a 3D vision foundation model specialized in oral anatomy to improve scan accuracy for complex dental structures. Arcreal raised $5.4 million (8 billion won) in a Pre-Series A round announced December 17, 2025 to advance its AI models and enter the US market, bringing cumulative funding to $9.6 million, per WOWTALE. The company plans to establish a US subsidiary in 2026.
Arcreal is a healthcare tool on Falcoscan. AI-powered intraoral scanner built in-house for dental clinics. Falcoscan rates Arcreal with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Arcreal is founded in 2021, currently at Series_a stage. Pricing: Paid.